Yorgancioglu A, et al. - Researchers assessed the effectiveness and tolerability of treatment with omalizumab for up to 5 years. During 1 year prior to omalizumab treatment and at 1, 3, and 5 years of treatment, comparisons were performed for documented exacerbations, hospitalizations, systemic steroid requirement, FEV₁, and asthma control test (ACT) results as well as adverse events and reasons for discontinuation. With omalizumab treatment, by 71.3% reduction in asthma exacerbation rate at 1 year, 64.3% at 3 years, and 54.8% at 5 years was achieved. Omalizumab decreased hospitalization rate and significantly improved ACT results. Overall, a significant impact of omalizumab on asthma outcomes was demonstrated, which was maintained over 5 years. The drug was found to be generally safe and treatment compliance was good.